Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026

Pharma-Bio Serv (OTCQB:PBSV) reported higher revenues and net income for the quarter and six months ended April 30, 2026.

Rhea-AI Summary

Pharma-Bio Serv (OTCQB:PBSV) reported higher revenues and net income for the quarter and six months ended April 30, 2026.

Quarterly revenue was approximately $2.7 million, with net income of $0.2 million. Six-month revenue reached $5.0 million and net income $0.3 million, both higher than last year.

Positive

• Quarter revenue about $2.7 million, up roughly $0.3 million year over year
• Six-month revenue about $5.0 million, up roughly $0.1 million
• Quarter net income about $0.2 million, increasing by roughly $0.1 million
• Six-month net income about $0.3 million, up approximately $0.2 million
• Management highlights focus on higher-return markets and cost discipline supporting results

Negative

• None.

Argus Jul 13 session

+2.65% close to close Open Argus

Details

News Market Reaction – PBSV

On Jul 13, the first trading day after this news, PBSV closed 2.65% above the previous close.

Data tracked by StockTitan Argus for the Jul 13 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DORADO, PR / ACCESS Newswire / June 15, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year.

Net income for the three and six months ended April 30, 2026, was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.

"We are encouraged by our results for the quarter, particularly the improvement in profitability," said Mr. Sanchez, Chief Executive Officer. "Our continued strategic focus on markets that offer the greatest opportunities for return, combined with disciplined cost management and operational efficiency, contributed to the improved financial performance."

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries to Puerto Rico, United States, Europe and Brazil markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787-278-2709

SOURCE: Pharma-Bio Serv, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Pharma-Bio Serv (PBSV) revenues for the quarter ended April 30, 2026?

Pharma-Bio Serv reported quarterly revenue of approximately $2.7 million for the period ended April 30, 2026. According to the company, this was about $0.3 million higher than in the same quarter of the prior year, reflecting improved top-line performance.

How much net income did Pharma-Bio Serv (PBSV) earn in the quarter ended April 30, 2026?

Pharma-Bio Serv recorded net income of approximately $0.2 million for the quarter ended April 30, 2026. According to the company, this represented an increase of about $0.1 million compared with the same quarter last year, indicating higher profitability.

What were Pharma-Bio Serv (PBSV) revenues for the six months ended April 30, 2026?

For the six months ended April 30, 2026, Pharma-Bio Serv generated revenue of approximately $5.0 million. According to the company, this was about $0.1 million higher than in the prior-year six-month period, showing modest revenue growth over that timeframe.

How did Pharma-Bio Serv (PBSV) six-month net income change by April 30, 2026?

Pharma-Bio Serv reported six-month net income of approximately $0.3 million for the period ended April 30, 2026. According to the company, this was about $0.2 million higher than the same period last year, reflecting stronger earnings performance.

What strategy did Pharma-Bio Serv (PBSV) link to its improved results in 2026?

Pharma-Bio Serv attributed its improved financial performance to focusing on markets offering better returns and disciplined cost management. According to the company, emphasizing operational efficiency and targeting higher-opportunity markets supported the reported increases in revenue and net income.